RRM1 and pancreatic neoplasm: Furthermore, cytotoxic effects after gemcitabine exposure were significantly increased in pancreatic cancer cells on treatment with RRM1-specific siRNA, relative to controls in both MIAPaCa2 and PSN1 cells (Fig 3B).